<DOC>
	<DOCNO>NCT02638961</DOCNO>
	<brief_summary>Heart failure ( HF ) preserve ejection fraction ( HFpEF ) become prevalent form HF develop country . Despite increase prevalence , evidence-based effective therapy HFpEF The purpose study evaluate whether inspiratory muscle training ( IMT ) , functional electrical stimulation ( FES ) , combination improve exercise capacity well leave ventricular diastolic function , biomarkers ' profile , quality life ( QoL ) prognosis patient HFpEF .</brief_summary>
	<brief_title>Inspiratory Muscle Training Functional Electrical Stimulation Treatment HFpEF</brief_title>
	<detailed_description>This study design prospective , control , randomize , four-armed , efficacy trial patient diagnosis HFpEF New York Heart Association functional class II-III/IV , diagnose accord criterion European Society Cardiology . A computer-generated randomization scheme use allocate participant ( 1:1:1:1 ratio ) receive : 1 ) home-based 12-week program inspiratory muscle training ( IMT ) ; 2 ) 12-week program functional electrical stimulation ( FES ) low limb muscle ; 3 ) standard treatment ( ST ) alone ; 4 ) combination IMT FES . The study conduct single center Spain . Independently stagger entry , minimum duration patient 's participation 6 month ( first last visit ) . All patient provide sign informed consent protocol approve research ethic committee center accordance principle Declaration Helsinki national regulation . Study population Candidate patient select outpatient 's clinic HF Hospital Clínico Universitario Valencia . Study objectives The primary endpoint study clinical endpoint three six month change peak oxygen uptake ( peak VO2 ) . Secondary endpoint three six month change echocardiogram parameter , QoL prognostic biomarkers . The investigator also specifically focus number episode worsen HF 6 month : 1 . Change E/e ' three six month . 2 . Change leave atrial volume index three six month . 3 . Change health-related QoL measure Minnesota Living With Heart Failure Questionnaire ( MLHF ) three six month . 4 . Change natriuretic peptide ( NT-proBNP ) three six month . 5 . Change minute ventilation/carbon dioxide production ( VE/VCO2 ) slope three six month . 6 . Number episodes acute HF hospitalization number episode worsen HF require hospitalization 6 month . Intervention Eligibility assessment screen visit After review inclusion/exclusion criterion sign informed consent form , comprehensive medical history , physical examination , anthropometry examination test perform . The examination test include : electrocardiogram ( ECG ) echocardiography , cardiopulmonary exercise testing ( CPET ) , 6-minute walk test ( 6-MWT ) , inspiratory muscle function test , QoL assessment Minnesota Living With Heart Failure Questionnaire ( MLHF ) blood sample panel baseline biomarkers . Finally , patient randomize ( 1:1:1:1 ) four group : 1 ) ST alone ; 2 ) home-based 12-week program IMT ; 3 ) 12-week program FES ; 4 ) combination IMT FES ( IMT+FES ) 12 week . 12-week six month visit All patient evaluate 12-week supervised training , six month randomization . Evaluation include medical history , physical examination , anthropometry functional QoL assessment test ( ECG , CPET , 6-MWT , inspiratory muscle function test , MLHF blood test ) .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Previous history symptomatic heart failure NYHA ( New York Heart Association ) functional class ≥II Normal leave ventricular ejection fraction : ejection fraction &gt; 0.50 Simpson method enddiastolic diameter &lt; 60 mm Structural heart disease : left ventricle hypertrophy/left atrial enlargement and/or diastolic dysfunction estimate 2D echocardiography Previous admission acute heart failure Clinical stability , without hospital admission past 3 month Perform valid baseline exercise test Significant primary moderate severe valvular disease Acute coronary syndrome cardiac surgery within previous three month Signs ischemia cardiopulmonary exercise test Significant primary pulmonary disease ; include pulmonary arterial hypertension , chronic thromboembolic pulmonary disease chronic obstructive pulmonary disease Any comorbidity expectancy life less one year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>heart failure preserve ejection fraction</keyword>
	<keyword>physical therapy</keyword>
	<keyword>exercise capacity</keyword>
	<keyword>quality life</keyword>
</DOC>